Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

LE SSERAFIM’s ‘CRAZY’ Dominates the Charts Again – Why Is It Surging Now?

Daniel Kim Views  

LE SSERAFIM’s CRAZY, released last August, is seeing a major comeback in popularity.

Source Music
Source Music

The K-pop group made waves when its mini album CRAZY and its title track appeared in the latest Billboard charts (January 11 edition), released on Tuesday.

The title track re-entered the charts, ranking 142nd on the Global Excl. U.S. chart and 179th on the Global 200. Both charts are based on online streaming and digital sales (downloads) from over 200 countries and regions worldwide. It’s imposing that the track, which dropped nearly five months ago, has returned to the charts.

In addition, CRAZY held steady at No. 12 on the World Albums chart and re-entered the Top Current Album Sales chart at No. 43.

The track’s resurgence is also evident on Spotify, the world’s largest music streaming platform. After 126 days since its release, CRAZY has surpassed 1.2 million daily streams for five consecutive days. This marks a notable increase compared to its average of about 900,000 daily streams in December.

Upon its release, LE SSERAFIM’s mini album CRAZY and its title track garnered international attention, breaking into both the Billboard 200 main album chart and the Hot 100 song chart. The group’s impact was further solidified when they ranked 46th in the Global 200 Artist category in Billboard’s 2024 Year-End Charts, marking the highest ranking for any K-pop girl group.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[ENTERTAINMENT] Latest Stories

  • How Real People Shaped Disney’s Most Beloved Animated Characters
  • General Motors Plans to Shift Truck Production to U.S. to Combat Tariff Impact
  • Could Squid Game’s Games Lead to Serious Health Risks? Doctors Reveal the Dangers
  • 'Squid Game' Season 2’s Massive Success—How Much Revenue Will It Make?
  • China’s Illegal 'Squid Game' Season 2 Merch Craze Raises Eyebrows and Anger
  • BTS Members’ Solo Projects Are Crushing It in 2025 – See the Latest Stats

You May Also Like

  • 1
    FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections

    LIFESTYLE 

  • 2
    Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds

    LIFESTYLE 

  • 3
    It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk

    LIFESTYLE 

  • 4
    Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

    LIFESTYLE 

  • 5
    Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer

    LIFESTYLE 

Popular Now

  • 1
    Tired of the Buzz? Fruit and Dairy Might Help, New Study Says

    LIFESTYLE 

  • 2
    Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients

    LIFESTYLE 

  • 3
    New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years

    LIFESTYLE 

  • 4
    New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects

    LIFESTYLE 

  • 5
    Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment

    LIFESTYLE 

Must-Reads

  • 1
    FDA Greenlights Sanofi's Qfitlia for Hemophilia—An Innovative Alternative to Daily Injections

    LIFESTYLE 

  • 2
    Prostate Cancer Screenings May Cut Death Risk in Half, Study Finds

    LIFESTYLE 

  • 3
    It’s Not Just Depression: Personality Disorders Linked to Highest Suicide Risk

    LIFESTYLE 

  • 4
    Faster Cancer Treatment? Merck Launch Set for Subcutaneous Keytruda Rollout

    LIFESTYLE 

  • 5
    Cutting Carbs? You Might Be Raising Your Risk of Colon Cancer

    LIFESTYLE 

Popular Now

  • 1
    Tired of the Buzz? Fruit and Dairy Might Help, New Study Says

    LIFESTYLE 

  • 2
    Study Finds Missing Gut Bacteria in Parkinson’s and IBD Patients

    LIFESTYLE 

  • 3
    New Research Reveals Ketogenic Diet Slows Biological Aging by 6+ Years

    LIFESTYLE 

  • 4
    New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects

    LIFESTYLE 

  • 5
    Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment

    LIFESTYLE 

Share it on...